Syndax Pharmaceuticals Discloses Updated Data From Multiple Combination Trials Of revumenib, The Company's Potent Small Molecule Menin Inhibitor, In Patients With Acute Leukemias
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals has disclosed updated data from multiple combination trials of revumenib, a potent small molecule Menin inhibitor, in patients with acute leukemias. The data shows promising results, with a 96% CRc observed in the BEAT AML trial and a 52% CRc in the AUGMENT-102 trial.
June 14, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals has reported promising data from trials of its Menin inhibitor, revumenib, in acute leukemias. The BEAT AML trial showed a 96% CRc, and the AUGMENT-102 trial showed a 52% CRc.
The high CRc rates in both trials indicate that revumenib has significant potential in treating acute leukemias, which is likely to positively impact Syndax Pharmaceuticals' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100